Jaeyoon Lee

Jaeyoon Lee

Auto-generated profile, based on publicly available information

Jaeyoon Lee

Physics Department & Laboratory of Atomic and Solid State Physics, Cornell University, Ithaca, NY, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKwon-Ho Song
Kwon-Ho Song
SOSe Jin Oh
Se Jin Oh
SKSuyeon Kim
Suyeon Kim
HCHanbyoul Cho
Hanbyoul Cho
HLHyo-Jung Lee
Hyo-Jung Lee
TKTae Woo Kim
Tae Woo Kim
Cancer immunotherapy has emerged as a promising cancer treatment. However, the presence of immune-refractory tumor cells limits its clinical success by blocking amplification of anti-tumor immunity. Previously, we found that immune selection by immunotherapy drives the evolution of tumors toward multi-modal resistant and stem-like phenotypes via transcription induction of AKT co-activator TCL1A by NANOG. Here, we report a crucial role of HSP90A at the crossroads between NANOG-TCL1A axis and multi-aggressive properties of immune-edited tumor cells by identifying HSP90AA1 as a NANOG transcriptional target. Furthermore, we demonstrate that HSP90A potentiates AKT activation through TCL1A-stabilization, thereby contributing to the multi-aggressive properties in NANOGhigh tumor cells. Importantly, HSP90 inhibition sensitized immune-refractory tumor to adoptive T cell transfer as well as PD-1 blockade, and re-invigorated the immune cycle of tumor-reactive T cells. Our findings implicate that the HSP90A-TCL1A-AKT pathway ignited by NANOG is a central molecular axis and a potential target for immune-refractory tumor.

1 January 2020 in Immune Network
Verified
Journal Article
Open access
SOSe Jin Oh
Se Jin Oh
JLJaeyoon Lee
Jaeyoon Lee
YKYukang Kim
Yukang Kim
KSKwon-Ho Song
Kwon-Ho Song
ECEunho Cho
Eunho Cho
TKTae Woo Kim
Tae Woo Kim
Cancer immunotherapy, in the form of vaccination, adoptive cellular transfer, or immune checkpoint inhibitors, has emerged as a promising practice within the field of oncology. However, despite the developing field's potential to revolutionize cancer treatment, the presence of immunotherapeutic-resistant tumor cells in many patients present a challenge and limitation to these immunotherapies. These cells not only indicate immunotherapeutic resistance, but also show multi-modal resistance to conventional therapies, abnormal metabolism, stemness, and metastasis. How can immunotherapeutic-resistant tumor cells render multi-malignant phenotypes? We reasoned that the immune-refractory phenotype could be associated with multi-malignant phenotypes and that these phenotypes are linked together by a factor that acts as the master regulator. In this review, we discussed the role of the embryonic transcription factor NANOG as a crucial master regulator we named "common factor" in multi-malignant phenotypes and presented strategies to overcome multi-malignancy in immunotherapeutic-resistant cancer by restraining the NANOG-mediated multi-malignant signaling axis. Strategies that blunt the NANOG axis could improve the clinical management of therapy-refractory cancer.

1 February 2020 in Biophysical Journal
Verified
Journal Article
Closed access
PDF file
TLTung T. Le
Tung T. Le
XGXiang Gao
Xiang Gao
SPSeong Ha Park
Seong Ha Park
JLJaeyoon Lee
Jaeyoon Lee
JIJames T. Inman
James T. Inman
MWMichelle D. Wang
Michelle D. Wang